It is well-established that a high incidence of p53 mutations exist in oral cavity squamous cell carcinomas (OCSCCs). To determine whether p53 mutations are etiologically associated with OCSCC development or are associated with exposure to specific carcinogens, we have analyzed the conserved regions of the p53 gene (exons 5-9) in 48 OCSCCs obtained from patients with varied tobacco and alcohol use histories by polymerase chain reaction/single strand confonnational polymorphism (PCR/SSCP) and DNA sequencing analysis. Thirty-eight percent (18/48) of the OCSCCs exhibited a mutation in exons 5-9 of the p53 gene. There was a significantly higher incidence of p53 mutations in OCSCCs from tobacco users (predominantly cigarette smokers) compared to those who had never used tobacco. No increase in the incidence of p53 mutation was observed in tobacco users who drank alcohol. G to A transitions and deletions were the predominant mutations observed in OCSCCs from tobacco users. No specific pattern of mutation was observed in OCSCCs from those subjects who had never used tobacco. These data suggest that a history of tobacco use was associated with a high incidence of p53 mutations in patients with OCSCC and that tobacco carcinogens induce a specific pattern of mutations in oral cavity tissue in vivo.
Introduction
Extensive epidemiological data have established that cigarette smoking, particularly when combined with chronic alcohol consumption, is the major risk factor for squamous cell carcinoma of the oral cavity, accounting for >75% of cases (1-3). Indeed, the relative risk for oral cavity cancer among heavy smokers and drinkers is >20 times that for non-smokers and non-drinkers (1). Although there is a slight increase in cancer risk resulting solely from heavy alcohol consumption (4), epidemiological evidence indicates that alcohol acts primarily as a cocarcinogen, enhancing the carcinogenicity of tobacco smoke up to 2-to 4-fold (1). In recent years, an increased incidence of oral cavity cancers, apparently unrelated
•Abbreviations: OCSCC, oral cavity squamous cell carcinoma; PCR, polymerase chain reaction; SSCP, single strand conformational polymorphism; SDS, sodium dodccylsulfate; LMP, low melting point; CpG, cytidine phosphate guanosine; C.I., confidence interval.
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to tobacco use and alcohol consumption, has been observed (5) (6) (7) (8) , suggesting that other risk factors also are involved in the etiology of oral cavity cancers.
Numerous studies have pointed to the importance of the p53 tumor suppressor gene in the process of carcinogenesis. In particular, a high incidence of p53 mutation has been demonstrated in tobacco-related cancers. For example, the incidence of p53 mutations in squamous cell carcinomas of the lung was shown to be as high as 82% (9) and have been observed in up to 63% of squamous cell carcinomas of the oral cavity (10) . An association between tobacco use and mutations of the p53 gene has similarly been made for bladder (11) and esophageal cancer (12) .
Previous studies have shown that certain carcinogens may induce a 'fingerprint'-like pattern of mutations at the p53 locus, both in terms of mutation type and codon specificity (13) . It has been demonstrated, for example, that UV light may be involved in the induction of p53 mutations in squamous cell carcinomas of the skin in individuals from New England and Sweden (14) . UV light was implicated in these tumors due to the presence of CC to TT double-base changes within the p53 gene in some of these tumors (CC to TT changes are UV-specific mutations not found in internal malignancies). In addition, hepatocellular carcinomas from individuals from southern Africa (15) or the Qidong Province of China (16) were found to contain mutations of the p53 gene in 50% of the cases analyzed. In 80-90% of these mutations, G to T transitions were observed, with the majority of these mutations located at codon 249 of the p53 gene. This type of mutation is consistent with mutations caused in vitro by aflatoxin B) (17,18), a known food contaminant in both of these regions. Therefore, the molecular targeting of specific carcinogens to the p53 locus can be elucidated in vivo with the aid of epidemiological data.
The role of p53 mutation in the etiology of oral cavity cancer has not yet been firmly identified. Previous studies have shown that the most common p53 mutational event in oral cavity cancers are G to A transitions (13) , an alteration commonly associated with tobacco use (19) . However, these studies have involved an analysis of relatively few oral cavity squamous cell carcinomas (OCSCCs*). In addition, few studies have focused on correlations between the observed pattern or incidence of p53 mutations in OCSCC with associated risk factors or carcinogen exposure. In this study, we examined 48 invasive OCSCCs for mutations in the conserved regions of the p53 gene and analyzed the pattern and incidence of mutations for correlations with patient tobacco and alcohol use. We demonstrate that the incidence of p53 mutations is high in OCSCCs and that the pattern and incidence of mutation correlates with patient tobacco use.
Materials and methods

Patients
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'See Clinical data section in Materials and methods for assessment of tobacco use and alcohol consumption. NS, never smoker, LS, light smoker; MS, moderate smoker; HS, heavy smoker.
, never drinker, LD, light drinker, MD, moderate drinker, HD, heavy drinker, nd, no data.
Center or the New York Eye and Ear Infirmary were prospecuvely entered into this study after approval by the appropriate institutional review boards. All tumors were obtained solely from anatomical sites within the oral cavity other than the lip, gum or hard palate, and not from other organ sites such as the larynx, and were immediately frozen at -70°C after surgical resection. An adjacent sample of normal oral cavity tissue was also resected from each patient at the time of surgery. Demographic data were collected from the hospital charts or patient interviews. The history of tobacco use and alcohol consumption was carefully documented by patient interview.
Clinical data
The laboratory was kept blinded to the clinical history of all subjects. Smoking history was quantified by pack-years of cigarettes smoked, and was classified as follows: never-smoker = <1 pack-year, light smoker = 1-20 pack-years; moderate smoker = 21-40 pack-years; heavy smoker = 5*40 pack-years; and ex-smoker = quit *5 years ago. Data were also collected on cigar, pipe and snuff use. Alcohol exposure was classified as: never-drinker = <0.1 shots/ day; light drinker = 0.1-1 shots/day; moderate drinker = 1.1-4.0 shots/day; heavy drinker = *4.0 shots/day; and ex-drinker = quit »5 years ago. One shot = 12.9 g of 43% alcohol, which is roughly equivalent to 1 oz of 86-proof hard liquor, one 3.6 oz glass of wine, or one 12 oz can of beer. Clinical data were also obtained on patient age and sex.
Isolation and purification of DNA Slices (100-500 mg) of partially thawed tumor or normal oral cavity tissue were quick-frozen in liquid nitrogen and pulverized with a blender. incubated in RNase A (1 |Xg/ml) at 37°C for 30 min, re-extracted with phenol/ chloroform, ethanol precipitated, rcsuspended in TE buffer and quantitated by spectrophotometry.
PCR amplification of the p53 gene
We amplified regions of the p53 gene known to contain most of the p53 mutations in human cancers (>95%), mainly, exons 5-9 (19) . The standard PCR was composed of a 100 \l\ reaction volume containing between 25 and 150 ng of purified genomic DNA, 50 mM KCI, 10 mM Tris-CI (pH 9.0), 1.5-3.0 mM MgCI 2 (depending on the primers utilized), 0.1% Triton X-100, 0.2 mM of each of the deoxynucleotide triphosphates (dATP, dCTP, dGTP, dTTP), 1.5 U of Taq DNA polymerase (Boehringer Mannheim), and 150-250 ng (25-40 pmol) of both sense and antisense primers. Reaction mixtures were incubated in a GenAmp 9600 thermocycler (Perkin Elmer) as follows: 100°C for 2 min, 32 cycles of 94°C for 15 s, 52-6O°C (depending on primers utilized) for 20 s, and 72°C for 20 s, followed by a final cycle at 72°C for 10 min. Samples were purified by band isolation after electrophoresis of PCR amplimers on 5% native polyacrylamide gels and ethidium bromide staining, incubation overnight in 0-5 M NH^AOc/l mM EDTA at 37°C and ethanol precipitated as previously described (20).
Primers
The following primers were used for PCR amplification and sequencing of p53 exons 5-9: exon 5, P553 (sense) -TTGTGCCCTGACTTTCAACT, P531 
Single strand conformational polymorphism (SSCP)
SSCP was performed by adding 1.0 u.1 of [a-32 P]dCTP (3000 Ci/mmol, 10 mCi/uJ; Amersham) into the above PCR mixture. Samples (2000-5000 c.p.m.s) of the PCR amplification mixture were lyophilized prior to the addition of 8 ul of dye mix (95% formamide, 20 mM EDTA (pH 8.0), 0.05% bromophenol blue, 0.05% xylene cyanol) and heated at 100°C for 10 min. Samples were cooled to 4°C and then immediately loaded onto a 0.4 mm thick MDE hydrolinlc gels (A.T. Biochem.) as per the manufacturer's protocol and electrophoresed at 6-30 W for 4-16 h with a cooling fan using a sequencing-type apparatus. SSCP electrophoresis was performed in gels both with and without 5% glycerol for all p53 exons analyzed, and was performed for both tumor and corresponding normal DNA for all tumor samples. After electrophoresis, gels were dried and autoradiographed.
All autoradiographs were examined by at least three individuals involved in this study to determine possible shifts in the banding patterns of p53 exons. A second round of SSCP analysis using the same genomic DNA preparation was performed for any sample exhibiting a possible shift in the first SSCP analysis. Those samples which exhibited a shift in both rounds of SSCP were considered to contain a p53 mutation and were sequenced as descnbed below.
Sequencing analysis
Samples exhibiung a shift in their p53 DNA banding pattern by PCR/SSCP analysis were examined directly using the dideoxy sequencing method of noneluted gel-purified PCR fragments (21) . Briefly, shifted bands were cut out of the dned SSCP gel, wetted with a few drops of xylene, immersed in 50-100 ul of H 2 O, and eluted overnight at 37°C prior to a second, non-radioactive round of PCR (up to 45 cycles) using the same primers used in the first round of PCR as described above. An aliquot of the PCR mixture (5-10%) was electrophoresed on a 5% PAGE for visual quantitation of amplimer concentration, and electrophoresis of a larger volume of PCR sample (40-90%) on an LMP agarose gel was subsequently performed. After cutting out the desired amplimer from the LMP gel, sequencing was performed for 0.3 pmol of non-eluted PCR template with the corresponding sense or antisense primers using the Sequenase v.o kit (United States Biochemical) and [ 33 S]-dATP (1000 Ci/mmol, 10 Ci/ml; Amersham) as outlined in the manufacturer's protocol. To rule out errors in sequencing, this analysis was performed for both sense and antisense primers. Base misincorporations induced by Taq DNA polymerase misreading were excluded by sequencing the shifted bands of two SSCP analyses arising from independent PCR products for each p53-mutated tumor sample.
Statistics
All comparative analysis was performed using the f} test.
Results
We assayed for p53 mutations in OCSCCs from 48 patients. A significant minority of these patients (7/48, 15%) were never-tobacco users; four of these drank alcohol (Table 1) . Twenty-nine percent of all patients were never-tobacco users or light (or ex-light) smokers (not including one light smoker who also smoked cigars). Thirty-two of the 39 patients who were tobacco users also drank alcohol (two smokers were not included in this analysis due to a lack of alcohol consumption data for these patients). The mean age of never-tobacco users (60 ± 11) was similar to that of all tobacco users (including ex-users; 61 ± 11). Twenty-four percent (10/41) of tobacco users and 71% (5/7) of never-tobacco users were female. NT, never tobacco users; LS, light smokers who did not use other forms of tobacco; MS, moderate smokers, including a light cigarette smoker who was also a cigar user, HS, heavy + ex-heavy smokers; OT, never smokers who used other forms of tobacco (i.e. pipe, cigar, snuff); ND, never drinkers; LD, light drinkers; MD, moderate drinkers; HD, heavy + ex-heavy drinkers; AD, any drinker. Tobacco and alcohol groups also contain ex-smokers or ex-drinkers for each of the respective categories. ''Two tumors, one of which was mutated in p53, were not included in the analysis on p53 mutation versus alcohol consumption, since no clinical data on alcohol consumption were available for these patients. 'Values in parentheses are a percentage of the total.
Exons 5-9 of the p53 gene contain >95% of the mutations observed in human cancers (19) . We screened 48 OCSCCs for mutations in this region by SSCP and DNA sequencing analysis. Thirty-eight percent (18/48) of the OCSCCs exhibited a mutation in exons 5-9 of the p53 gene (Table I) . Ten of the mutations were missense, resulting in amino acid changes, while an additional three mutations were nonsense, encoding translational stop codons (Figures 1 and 2) . The remaining five mutations were deletions. Four of the deletions were of a single base pair, resulting in frameshift mutations, while one was a deletion of 10 nt at the 5' end of intron 7, resulting in a splice site mutation at the 3' end of exon 6. Three additional tumor samples exhibited shifts in the banding pattern of p53 exon 6 by SSCP analysis. In all cases, sequencing analysis revealed the presence of a CGA->CGG polymorphism in codon 213 of the p53 gene.
Fifty percent of the OCSCCs from patients who were moderate to heavy smokers (including ex-heavy smokers and a light smoker who was also a cigar user) exhibited mutations in exons 5-9 of the p53 gene (Table II) . By contrast, OCSCCs from patients who never used tobacco or were light or exlight smokers exhibited a significantly lower incidence of p53 mutations (14%) than tumors from moderate to heavy smokers (P < 0.025). The incidence of p53 mutations was similar in never-tobacco users as compared to light smokers. Neither of the OCSCCs from never-smokers who used other forms of tobacco contained a p53 mutation.
There was no significant difference in the incidence of p53 mutations in OCSCCs from, (i) never-alcohol users (36%), (ii) light alcohol users (20%), (iii) moderate alcohol users (33%), or (iv) heavy alcohol users (45%; see Table II ). No increase in the incidence of p53 mutations was observed in OCSCCs from all alcohol-users versus non-users in patients who were moderate to heavy smokers (Table II) . In addition, no increase in the p53 mutation incidence was observed in OCSCCs from moderate to heavy smokers who were heavy drinkers as compared to moderate to heavy smokers who were non-alcohol users (Table II) .
A specific pattern of mutation was observed in exons 5-9 of the p53 gene in OCSCCs from smokers (Table m) . Six of the sixteen mutations in OCSCCs from moderate to heavy smokers were G:C to A:T transitions. All six of these patients also used alcohol. By contrast, neither of the two p53 mutations in OCSCCs from light or never-smokers were G:A to A:T transitions. In addition, four of the mutations in OCSCCs from moderate to heavy smokers were base pair deletions while an additional three mutations were G:C to T:A transversions. Mutations were observed at cytidine phosphate guanosine (CpG) dinucleotides, sites which are susceptible to endogeneous methylation, spontaneous deamination and base pair misincorporation, in six of the sixteen mutations in OCSCCs from moderate to heavy smokers but neither of the OCSCCs from never-or light-smokers. All of the mutations observed in OCSCCs from this series of patients were somatic and not germ-line in origin, as DNA from normal tissue adjacent to p53-mutated tumor was negative for p53 mutations by both PCR/SSCP and DNA sequencing analysis (Figures 1 and 2 ) for all p53 exons examined for all patients.
Discussion
The high incidence of p53 mutations in oral cavity tumors observed in previous studies (13) was confirmed in the present study. We attempted to expand the analysis of these data to examine the incidence and/or pattern of mutations in the p53 gene for correlations with known risk factors for oral cavity cancer, specifically, tobacco use and alcohol consumption. Patients who were moderate to heavy smokers were 6.0 times more likely to contain p53-mutated OCSCCs than patients who never used tobacco or who were only light smokers (P < 0.025; C.I. = 1.15-31.2). This is similar to the pattern of p53 mutation incidence observed in head and neck cancer (22) . In addition, the most prevalent p53 mutations types found in OCSCCs from moderate to heavy smokers in our study were, (i) G:C to A:T transitions, and (ii) deletions. This is similar to the pattern of p53 mutations observed in oral cavity tumors in other studies (13) . In addition, G:C to A:T transitions within codon 12 of the Ki-ras oncogene were the predominant mutation in lung adenocarcinomas induced by 4-(methylnitrosamino)-l-(3-pyridyl)-l-butanone, a strong rodent tobacco-specific carcinogen, in A/J mice and Syrian golden hamsters (23, 24) . Therefore, our studies strongly suggest that both the pattern and incidence of p53 mutations are correlated with patient tobacco use. As only two p53 mutations were observed in OCSCCs from never-tobacco users or light smokers, we could not utilize p53 mutational spectrum to provide information on tumor causality in these individuals. In addition, our results suggest that the induction of p53 mutations may be dependent on the levels of tobacco exposure since only moderate to heavy and not light smokers exhibited a higher incidence of p53 mutations as compared to never tobacco users.
No apparent relationship was observed between patient alcohol use and the incidence of p53 mutations in OCSCCs in our study. In addition, no increase in the incidence of p53 mutations was observed in OCSCCs from alcohol-using versus non-using moderate to heavy smokers. These data suggest that alcohol does not potentiate the induction of p53 mutations in OCSCCs by tobacco carcinogens. This contrasts with results obtained by Brennan et al., who found that a synergism exists between the use of both tobacco and alcohol and the induction of p53 mutations in head and neck tumors (22) . This difference between the two studies could be due to, (i) the low number of moderate to heavy smokers who were never alcohol users in our study, or (ii) our analysis was limited to an analysis of oral cavity instead of head and neck squamous cell carcinomas.
Previous studies have utilized both genetic (13) and immunohistochemical (25, 26) analysis to link alterations in p53 with oral cavity or head and neck cancer. In our studies, 8 of the 18 (45%) p53 mutations observed in OCSCCs resulted in frameshifts, splice site mutations or premature translational stop codons. In all cases, these mutations would encode truncated p53 protein and would not likely be detected by immunohistochemical analysis. As noted by Brennan et al. for head and neck cancer (22) , this would result in a large number of false negative data for p53 alterations within this series of tumors. This is particularly important for studies of p53 mutation incidence in oral cavity cancer, since frameshifts are the second most common mutation observed for this tumor type after G:C to A:T transitions (13) . Therefore, immunohistochemical analysis may not always be an effective surrogate measure of p53 mutation incidence for OCSCC.
We had previously demonstrated that the incidence of p53 mutations in oral cavity premalignant lesions is low in nevertobacco users and may be correlated with patient tobacco use (27) . Since inactivation of the p53 gene appears to play a critical role in the tumorigenic process, these results suggested that mutations of the p53 gene may play an integral role in the progression of oral cavity cancer. In this report, we have shown that the correlation between p53 mutation incidence and patient tobacco use is observed for OCSCC. Therefore, tobacco carcinogens may target cells for tumor promotion by inactivation of the p53 gene. These data further support abstinence from smoking as a mechanism for the prevention of oral cavity cancer.
